Wintermute Biomedical participated in BioJapan 2024, engaging with pharmaceutical and biotechnology organisations and developing new relationships across Japan and the broader Asia-Pacific life sciences sector.
Wintermute Biomedical participated in BioJapan 2024 in Yokohama, one of Asia’s leading biotechnology partnering events.
Bringing together biotechnology and pharmaceutical companies, academic institutions, investors and business development leaders, BioJapan provides an important platform for international collaboration across the life sciences sector.
Wintermute’s participation provided an opportunity to introduce Solexan™, our investigational topical antiviral being developed for the treatment of herpes zoster (shingles), to potential pharmaceutical and strategic partners from Japan and across the Asia-Pacific region.
Japan represents an important global pharmaceutical market with a strong history of innovation in drug development and infectious disease.
During BioJapan, Wintermute participated in partnering and business development discussions aimed at building relationships with organisations whose expertise and capabilities could support the future development and commercialisation of Solexan™.
Our participation at BioJapan formed part of Wintermute Biomedical’s broader international business development strategy.
The relationships established through events such as BioJapan provide opportunities for continued dialogue with potential pharmaceutical, development and commercial partners as the Solexan™ clinical programme progresses.
Wintermute looks forward to continuing to strengthen its relationships within the Japanese and broader Asia-Pacific life sciences communities.